CHA
ATYR

Carmichael Hill & Associates’s aTyr Pharma ATYR Stock Holding History

Carmichael Hill & Associates’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300
Closed -$3K – 841
2021
Q3 		$3K Buy
+300
New +$1.79K ﹤0.01% 737

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Carmichael Hill & Associates's ATYR Position: Q4 2021 in Review

Carmichael Hill & Associates sold out of aTyr Pharma (ATYR) in Q4 2021, closing a stake of 300 shares — an estimated $3K sold.

Carmichael Hill & Associates first reported a position in ATYR in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 47 funds tracked by Wall St. Rank hold ATYR as of Q4 2021.

  • Carmichael Hill & Associates reported no remaining aTyr Pharma position as of Q4 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 300 aTyr Pharma shares in Q4 2021, an estimated $3K.
  • Carmichael Hill & Associates first reported a position in aTyr Pharma in Q3 2021 and held it in 1 quarter.
  • Carmichael Hill & Associates's aTyr Pharma position peaked at $3K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2021.

Based on Carmichael Hill & Associates's 13F filing for Q4 2021, filed 31 Jan 2022.